High‑level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma

Chen,Dong; Li,Tieling; Wang,Cheng; Lei,Guanglin; Wang,Ruilan; Wang,Zhaohai; Yu,Linxiang; Yan,Jin; Zhang,Peirui; Wang,Xiliang; Zhang,Shaogeng; Yang,Penghui

doi:10.3892/mmr.2019.9832

High‑level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma

Authors:
- Dong Chen
- Tieling Li
- Cheng Wang
- Guanglin Lei
- Ruilan Wang
- Zhaohai Wang
- Linxiang Yu
- Jin Yan
- Peirui Zhang
- Xiliang Wang
- Shaogeng Zhang
- Penghui Yang
View Affiliations

Affiliations: Hepatobiliary Department, Beijing 302 Hospital, Beijing 100039, P.R. China, Department of Cardiology, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China, State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P.R. China
Published online on: January 8, 2019 https://doi.org/10.3892/mmr.2019.9832
Pages: 1587-1594
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The SET domain‑containing 1B (SETD1B) gene is involved in multiple biological processes, including tumor development and progression. However, the role of SETD1B in hepatocellular carcinoma (HCC) is largely unexplored. The present study, examined the expression of SETD1B in patients with HCC and assessed its clinical significance. Reverse transcriptase quantitative polymerase chain reaction and western blot analysis results revealed that the expression levels of SETD1B mRNA and protein were significantly increased in HCC tumor tissues compared with the adjacent normal tissues. In addition, an analysis of the patient clinical factors indicated that increased levels of SETD1B expression were associated with tumor size, clinical stage and liver cirrhosis. Patients with HCC with decreased levels of SETD1B expression exhibited longer survival times compared with those with increased levels of SETD1B expression. In addition, Cox's regression analysis results implied that the upregulation of SETD1B was an independent prognostic marker in patients with HCC. Taken together, the results demonstrated that SETD1B is essential in the progression of HCC and may be used as a potential prognostic marker and therapeutic target in HCC.

View Figures

View References

1	Yang Y, Zhou Y, Hou J, Bai C, Li Z, Fan J, Ng IOL, Zhou W, Sun H, Dong Q, et al: Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma. Hepatology. 66:152–166. 2017. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
3	Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, et al: Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol. 31:4067–4075. 2013. View Article : Google Scholar : PubMed/NCBI
4	Lee JH, Tate CM, You JS and Skalnik DG: Identification and characterization of the human Set1B histone H3-Lys4 methyltransferase complex. J Biol Chem. 282:13419–13428. 2007. View Article : Google Scholar : PubMed/NCBI
5	Duncan EM, Chitsazan AD, Seidel CW and Alvarado AS: Set1 and MLL1/2 target distinct sets of functionally different genomic loci in vivo. Cell Rep. 17:9302016. View Article : Google Scholar : PubMed/NCBI
6	Li Y, Han J, Zhang Y, Cao F, Liu Z, Li S, Wu J, Hu C, Wang Y, Shuai J, et al: Structural basis for activity regulation of MLL family methyltransferases. Nature. 530:447–452. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhang BL, Ji X, Yu LX, Gao Y, Xiao CH, Liu J, Zhao DX, Le Y, Diao GH, Sun JY, et al: Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. Oncol Lett. 16:6003–6012. 2018.PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Li J, Wu H, Li W, Yin L, Guo S, Xu X, Ouyang Y, Zhao Z, Liu S, Tian Y, et al: Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene. 35:5501–5514. 2016. View Article : Google Scholar : PubMed/NCBI
10	Davie JR, Xu W and Delcuve GP: Histone H3K4 trimethylation: Dynamic interplay with pre-mRNA splicing. Biochem Cell Biol. 94:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yang W and Ernst P: Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis. Curr Opin Hematol. 24:322–328. 2017. View Article : Google Scholar : PubMed/NCBI
12	Hiraide T, Nakashima M, Yamoto K, Fukuda T, Kato M, Ikeda H, Sugie Y, Aoto K, Kaname T, Nakabayashi K, et al: De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism. Hum Genet. 137:95–104. 2018. View Article : Google Scholar : PubMed/NCBI
13	Schmidt K, Zhang Q, Tasdogan A, Petzold A, Dahl A, Arneth BM, Slany R, Fehling HJ, Kranz A, Stewart AF and Anastassiadis K: The H3K4 methyltransferase Setd1b is essential for hematopoietic stem and progenitor cell homeostasis in mice. Elife. 7:e271572018. View Article : Google Scholar : PubMed/NCBI
14	Redd PS, Ibrahim ML, Klement JD, Sharman SK, Paschall AV, Yang D, Nayak-Kapoor A and Liu K: SETD1B activates iNOS expression in myeloid-derived suppressor cells. Cancer Res. 77:2834–2843. 2017. View Article : Google Scholar : PubMed/NCBI
15	Brici D, Zhang Q, Reinhardt S, Dahl A, Hartmann H, Schmidt K, Goveas N, Huang J, Gahurova L, Kelsey G, et al: Setd1b, encoding a histone 3 lysine 4 methyltransferase, is a maternal effect gene required for the oogenic gene expression program. Development. 144:2606–2617. 2017. View Article : Google Scholar : PubMed/NCBI
16	Lin H, Min Z and Tao Q: The MLL/Setd1b methyltransferase is required for the Spemann's organizer gene activation in Xenopus. Mech Dev. 142:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
17	Choi YJ, Oh HR, Choi MR, Gwak M, An CH, Chung YJ, Yoo NJ and Lee SH: Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum Pathol. 45:1674–1681. 2014. View Article : Google Scholar : PubMed/NCBI
18	Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 509:91–95. 2014. View Article : Google Scholar : PubMed/NCBI
19	Medjkane S, Cock-Rada A and Weitzman JB: Role of the SMYD3 histone methyltransferase in tumorigenesis: Local or global effects? Cell Cycle. 11:18652012. View Article : Google Scholar : PubMed/NCBI
20	Tang B, Qi G, Tang F, Yuan S, Wang Z, Liang X, Li B, Yu S, Liu J, Huang Q, et al: JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells. Oncotarget. 6:12723–12739. 2015. View Article : Google Scholar : PubMed/NCBI